Advertisement

Neurophysiology

, Volume 50, Issue 3, pp 159–165 | Cite as

Levels of Thyroid Hormones and Indices of Energy Metabolism in the Cerebral Cortex of Rats with Experimental Alzheimer’s Disease

  • T. V. Gorbach
  • O. A. Nakonechna
  • A. S. Tkachenko
  • T. S. Shcholok
  • A. O. Onikova
Article
  • 1 Downloads

The study was carried out on 30 mature WAG rats, 15 intact control animals and 15 rats with modeled Alzheimer’s disease (AD) induced by course injections of scopolamine (27 days, 1 mg/kg, i.p. daily). The contents of ATP, glucose, pyruvate, and lactate were measured spectrophotometrically in homogenates of the brain cortex of the animals. The levels of TSH, T3, and T4 in blood serum and those of T3 and T4 in cortex homogenates were estimated using ELISA. The activities of pyruvate dehydrogenase, creatine phosphokinase, and key enzymes of the tricarboxylic acid cycle (TCA) were measured in the mitochondria using a spectrophotometric technique. It was found that the content of T3 in the brain cortex of rats was much lower than in the controls against the background of higher T4 concentrations, which was indicative of the development of local hypothyroidism in the brain. The increased activity of pyruvate dehydrogenase against the background of low activities of TCA cycle enzymes in brain homogenates was observed. The decreased creatine kinase activity and low ATP contents were also found. Local hypothyroidism in the brain cortex is believed to be one of the significant factors inducing the development of strong energy deficiency and reducing the activity of Krebs cycle enzymes. Consequently, this contributes to the death of neurons in experimental AD in rats.

Keywords

Alzheimer’s disease scopolamine energy metabolism thyroid hormones ATP rats 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. V. Vinters, “Emerging concepts in Alzheimer’s disease,” Annu. Rev. Pathol., 10, 291-319 (2015).CrossRefGoogle Scholar
  2. 2.
    A. Kumar, A. Singh, and Ekavali, “A review on Alzheimer ’s disease pathophysiology and its management: an update,” Pharmacol. Rep., 67, No. 2, 195-203 (2015).CrossRefGoogle Scholar
  3. 3.
    G. J. McBean, M. G. López, and F. K. Wallner, “Redoxbased therapeutics in neurodegenerative disease,” Br. J. Pharmacol., 174, No. 12, 1750-1770 (2017).CrossRefGoogle Scholar
  4. 4.
    B. P. Lucke-Wold, R. C. Turner, A. F. Logsdon, et al., “Common mechanisms of Alzheimer’s disease and ischemic stroke: the role of protein kinase C in the progression of age-related neurodegeneration,” J. Alzheimers Dis., 43, No. 3, 711-724 (2015).CrossRefGoogle Scholar
  5. 5.
    J. Z. Wang, Y. Y. Xia, I. Grundke-Iqbal, and K. Iqbal, “Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration,” J. Alzheimer`s Dis., 33, Suppl. 1, 123-139 (2013).Google Scholar
  6. 6.
    M. Kolarova, F. García-Sierra, A. Bartos, et al., “Structure and pathology of tau protein in Alzheimer disease,” Int. J. Alzheimer`s Dis., 731526; doi: 10.1155/2012/731526 (2012).Google Scholar
  7. 7.
    M. Domise, S. Didier, C. Marinangeli, et al., “AMPactivated protein kinase modulates tau phosphorylation and tau pathology in vivo,” Sci. Rep., 6, 26758; doi:  https://doi.org/10.1038/srep26758 (2016).CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    T. Kanekiyo, H. Xu, and G. Bu, “ApoE and Aβ in Alzheimer’s disease: Accidental encounters or partners?” Neuron, 81, No. 4, 740-754 (2014).CrossRefGoogle Scholar
  9. 9.
    C. C. Liu, C. C. Liu, T. Kanekiyo, et al., “Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy,” Nat. Rev. Neurol., 9, No. 2, 106-118 (2013).CrossRefGoogle Scholar
  10. 10.
    A. N. Mironova, Manual for Carrying Out Preclinical Studies of Pharmacological Agents, Part 1, Grif and Co., Moscow (2012).Google Scholar
  11. 11.
    R. D. Deyko, C. Yu. Shtrygol’, T. V. Gorbach, et al., “Nootropic properties of a tetrapeptide, Acetyl-(DLys)-Lys-Arg-Arg-Amide (KK-1), in a rat model of Alzheimer’s disease induced by chronic introduction of scopolamine,” Klin. Farmats., 20, No. 4, 52-61 (2016).Google Scholar
  12. 12.
    M. I. Prokhorova, Methods of Biochemical Studies (Lipid and Energetic Metabolism), Publ. House of the Leningrad University, Leningrad (1982).Google Scholar
  13. 13.
    D. J. Selkoe and J. Hardy, “The amyloid hypothesis of Alzheimer’s disease at 25 years,” EMBO Mol. Med., 8, No. 6, 595-608 (2016).CrossRefGoogle Scholar
  14. 14.
    L. C. Costantini, L. J. Barr, J. L. Vogel, and S. T Henderson, “Hypometabolism as a therapeutic target in Alzheimer’s disease,” BMC Neurosci., 9, Suppl. 2, S16; doi:  https://doi.org/10.1186/1471-2202-9-S2-S16 (2008).CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    G. S. Bloom, “Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis,” JAMA Neurol., 71, No. 4, 505-508 (2014).CrossRefGoogle Scholar
  16. 16.
    Y. Deng, B. Li, Y. Liu, et al., “Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain implication for Alzheimer’s disease,” Am. J. Pathol., 175, No. 5, 2089-2098 (2013).CrossRefGoogle Scholar
  17. 17.
    R. R. Attia, S. Connnaughton, L. R. Boone, et al., “Regulation of pyruvate dehydrogenase kinase 4 (PDK4) by thyroid hormone: role of the peroxisome proliferatoractivated receptor gamma coactivator (PGC-1 alpha),” J. Biol. Chem., 285, No. 4, 2375-2385 (2010).CrossRefGoogle Scholar
  18. 18.
    J. H. Duncan Bassett, “Thyroid hormone action: Genomic and non-genomic effects,” Endocrine Abstr., 25, S6.1 (2011).Google Scholar
  19. 19.
    J. Y. Kim, N. Kim, Z. Zheng, et al., “The 70 kDa heat shock protein protects against experimental traumatic brain injury,” Neurobiol. Dis., 58, 289-295 (2013).CrossRefGoogle Scholar
  20. 20.
    I. V. Gorodetskaya, A. P. Bozhko, L. Y. Bakhtina, and I. Yu. Malyshev, “Role of thyroid hormones in stress-induced synthesis of heat-shock proteins in the myocardium,” Bull. Exp. Biol. Med., 130, No. 12, 1138-1140 (2000).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Kharkiv National Medical UniversityKharkivUkraine

Personalised recommendations